Skip to main content
S&P 5007,656.98+0.86%DOW52,573.29+0.98%NASDAQ26,333.03+0.96%BTC$77,267.00+0.58%ETH$2,510.86+2.27%GOLD$4,390.00-0.39%OIL$99.99-2.43%
Smart Investors Daily
CN

NASDAQ · CNSP

CNS Pharmaceuticals, Inc.

Healthcare · Biotechnology

$5.84

Up+$0.09 (+1.57%)

Updated Sep 14, 2026, 1:55 AM

SID Score

4.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
4.42M
P/E ratio
-0.02
Dividend yield
0.00%
52-week range
$1.90 – $10.59
Volume
18.54K
Avg. volume
27.9K

Price performance

CNSP price history

1M range · 19 trading sessions · Daily adjusted prices

CNSP closed at $5.84 after 19 trading sessions, up 8.15% for the selected period.

Last close
$5.84
Period change
+8.15%
Period low
$5.40
Period high
$6.01
Daily close
View OHLC price history
CNSP OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 11, 2026$5.845$5.845$5.73$5.8418.54K
Sep 10, 2026$5.79$5.79$5.75$5.751.58K
Sep 9, 2026$5.89$5.94$5.76$5.782.73K
Sep 8, 2026$5.64$5.99$5.64$5.9410.56K
Sep 4, 2026$5.86$5.916$5.73$5.734.81K
Sep 3, 2026$6.00$6.00$5.60$5.88661.66K
Sep 2, 2026$5.91$6.01$5.745$6.0119.67K
Sep 1, 2026$5.77$5.8921$5.77$5.89211.89K
Aug 31, 2026$5.63$5.98$5.61$5.985.08K
Aug 28, 2026$5.70$5.79$5.4774$5.52293.72K
Aug 27, 2026$5.57$5.80$5.50$5.51747.17K
Aug 26, 2026$5.8001$5.81$5.44$5.446.96K
Aug 25, 2026$5.74$6.05$5.7394$5.808.56K
Aug 24, 2026$5.71$6.1899$5.60$5.9418.79K
Aug 21, 2026$5.965$6.05$5.83$5.838.11K
Aug 20, 2026$5.71$6.0763$5.71$6.004.19K
Aug 19, 2026$6.07$6.19$5.7001$5.8321.43K
Aug 18, 2026$5.30$6.15$5.30$5.861527.08K
Aug 17, 2026$5.51$5.81$5.40$5.403.73K

Latest CNSP news

The latest Smart Investors Daily articles mentioning CNSP.

Stock researchCompany · Overview

CNSP research

Overview

Company profile and research snapshot.

Company profile

CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$0.50
Implied upside
—
Analysts
—
CNSP recent ratings
DateFirmRatingTarget
Sep 12, 2025Maxim GroupBuy—
Mar 25, 2025Maxim GroupHold—
Sep 10, 2024Maxim GroupBuy—
Feb 2, 2021Brookline CapitalBuy—
Aug 24, 2020Ladenburg ThalmannBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 1, 2026

CNS Pharmaceuticals Details Business Development Strategy Driving Its Next Phase of Growth

Chief Business Officer, Dylan Wenke, Participates in Virtual Investor "What This Means" SegmentAccess the segment hereHOUSTON, TX / ACCESS Newswire / September 1, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in a Virtual Investor "What This Means" Segment.Dylan Wenke, Chief Business Officer of CNS Pharmaceuticals, provided an update on

Yahoo · Aug 27, 2026

CNS Pharmaceuticals Participates in the Virtual Investor "Why Now" On-Demand Conference

Video webcast now available hereHOUSTON, TX / ACCESS Newswire / August 27, 2026 / (NASDAQ:CNSP) ("CNS" or the "Company"), a biotechnology company focused on building a pipeline of innovative therapies addressing significant unmet medical needs, today announced that it participated in the Virtual Investor "Why Now" on-demand conference.Rami Levin, President and Chief Executive Officer of CNS Pharmaceuticals, highlighted the Company's strategic transformation that is being built on the strength of

Benzinga · Aug 12, 2026

CNS Pharmaceuticals Q2 EPS $(0.38) Misses $(0.24) Estimate

CNS Pharmaceuticals (NASDAQ:CNSP) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.24) by 58.33 percent. This is a 94.08 percent increase over losses of $(6.42) per share

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By